LYEL
Lyell Immunopharma, Inc.
Next earnings Aug 10, 2026 · consensus $-2.07 EPS, $4.69K rev
Last earnings +1.1% on 2026-05-06
$11.61
▼ -7.05%$11.61▲ +29.14%
over 1Y
L $8.84EODHDH $38.60
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-7.0%
1W-3.0%
1M-30.6%
3M-41.0%
YTD-59.9%
1Y+29.1%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy
Conservative balance sheet (liabilities/equity 0.37x); but revenue fell -41.0% YoY.
Revenue (FY2025) $36.0K · FY2025
Lyell Immunopharma, Inc. shows $36.0K in FY2025 revenue (-41.0% YoY), a -762355.6% net margin, and -110.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $10.7M | $84.7M | $130K | $61.0K | $36.0K |
| Gross profit | — | — | — | — | — |
| Operating income | -$215M | -$187M | -$247M | -$359M | -$269M |
| Net income | -$250M | -$183M | -$235M | -$343M | -$274M |
| Diluted EPS | -$1.84 | -$0.74 | -$18.70 | -$26.23 | -$16.06 |
| Net margin | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$210M
EV / EBITDA—
EV / Sales5844.9
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-101.4%
FCF yield-55.7%
Quality & risk
ROIC (est.)-85.7%
Free cash flow-$151M
Total debt—
Net cash$60.2M
Altman Z-Score-6.77 distress
Piotroski F-Score2/7
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY-92.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-152026-06-18open ↗SCHEDULE 13G/AFiling2026-06-18open ↗3Period ending 2026-05-182026-06-18open ↗4Period ending 2026-05-112026-06-15open ↗4Period ending 2026-05-112026-06-15open ↗4Period ending 2026-05-112026-06-15open ↗4Period ending 2026-05-112026-06-15open ↗8-KPeriod ending 2026-06-102026-06-15open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2025-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗
Frequently asked
- Is Lyell Immunopharma, Inc. (LYEL) a buy?
- LYEL currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.37x); but revenue fell -41.0% YoY.
- What is Lyell Immunopharma, Inc.'s quality score?
- LYEL scores 37.745098039215684/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001806952, latest 10-Q filed 2026-05-06) · EODHD · as of 6/26/2026, 7:45:36 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.